Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: Structure-function relationships for nanoscale amphiphilic polymers

Acta Biomaterialia

Volumn 6, Issue 8, 2010, Pages 3081-3091

  Iverson, Nicole M ^a   Sparks, Sarah M ^b   Demirdirek, Bahar ^b   Uhrich, Kathryn E ^b   Moghe, Prabhas V ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c The State University of New Jersey   (United States)

Author keywords

Biomaterials; Low density lipoproteins; Macrophages; Nanoassemblies; Polymers

Indexed keywords

BODY FLUIDS; CARBOXYLIC ACIDS; HYDROPHILICITY; HYDROPHOBICITY; LIPOPROTEINS; MACROMOLECULES; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLYETHYLENE GLYCOLS; POLYETHYLENES;

AMPHIPHILIC MACROMOLECULES; ANIONIC CHARGE; CELLULAR UPTAKE; HUMAN MACROPHAGES; HYDROPHOBICS; LOW DENSITY LIPOPROTEINS; MACROPHAGE CELLS; NANO SCALE; NANO-ASSEMBLIES; OXIDIZED LOW-DENSITY LIPOPROTEINS;

MACROPHAGES;

ALIPHATIC CARBOXYLIC ACID; AMPHIPHILIC MACROMOLECULE; LOW DENSITY LIPOPROTEIN; MACROGOL; POLYMER; UNCLASSIFIED DRUG; ANION; CARBOXYLIC ACID; MACROGOL DERIVATIVE; NANOMATERIAL; OXIDIZED LOW DENSITY LIPOPROTEIN;

ARTICLE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROMOLECULE; MACROPHAGE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION; CELL LINE; CHEMISTRY; DRUG EFFECT; ENDOCYTOSIS; HYDROPHOBICITY; METABOLISM; PARTICLE SIZE; ROTATION; SYNTHESIS;

ANIONS; CARBOXYLIC ACIDS; CELL LINE; ENDOCYTOSIS; HUMANS; HYDROPHOBICITY; LIPOPROTEINS, LDL; MACROPHAGES; NANOSTRUCTURES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYMERS; ROTATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77956642537     PISSN: 17427061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actbio.2010.02.019     Document Type: Article

References (48)

1. Glass C, Witztum J. Atherosclerosis: the road ahead. Cell 2001; 104 (4): 503-16.
2. Bradley M, Hong C, Chen M, Joseph S, Wilpitz D, Wang X, et al. Ligand activation of LXRb reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRa and apoE. J Clin Invest 2007;117:2337-46.
3. Lusis A. Atherosclerosis. Nature (London) 2000; 407 (6801): 233-41.
4. Gimbrone Jr M. Endothelial dysfunction, hemodynamic forces, and atherosclerosis. Thromb Haemost 1999; 82 (2): 722-6.
5. Goldstein J, Ho Y, Basu S, Brown M. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76 (1): 333-7.
6. Goldstein J, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76 (1): 333-7.
7. Lougheed M, Lum C, Ling W, Suzuki H, Tatsuhiko K, Steinbrecher U. High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II. J Biol Chem 1997; 272 (20): 12938-44. (Pubitemid 27216709)
8. Berliner J, Heinecke J. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20 (5): 707-27.
9. Ramprasad M, Valeska T, Kondratenko N, Quehenberger O, Steinberg D. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for ozidized low density lipoprotein. Proc Natl Acad Sci USA 1996; 93 (25): 14833-8.
10. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272 (34): 20963-6.
11. Hiltunen T, Yla-Herttuala S. Expression of lipoprotein receptors in atherosclerotic lesions. Atherosclerosis 1998; 137 (Suppl): s81-8.
12. De Winther M, Van Dijk K, Havekes L, Hofker M. Macrophage scavenger receptor class A: a multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20 (2): 290-7. (Pubitemid 30086083)
13. Podrez E, Febbraio M, Sheibani N, Schmitt D, Silverstein R, Hajjar D, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000; 105 (8): 1095-108.
14. Zaman A, Helft G, Worthley S, Badimon J. The role of plaque rutpture and thrombosis in coronoary artery disease. Atherosclerosis 2000; 149 (2): 251-66.
15. Nicholson A, Han J, Febbraio M, Silverstein R, Hajjar D. Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. Ann NY Acad Sci 2001;947:224-8.
16. Yoshimoto T, Takahashi Y, Kinoshita T, Sakashita T, Inoue H, Tanabe T. Growth simulation and epidermal growth factor receptor induction in clyclooxygenase-overexpressing human colon carcinoma cells. Adv Exp Med Biol 2002;507:403-7.
17. Chnari E, Lari H, Tian L, Uhrich K, Moghe P. Nanoscale anionic macromolecules for selective retention of low-density lipoproteins. Biomaterials 2005; 26 (17): 3749-58.
18. Chnari E, Nikitczuk J, Uhrich K, Moghe P. Nanoscale anionic macromolecules can inhibit cellular uptake of differentially oxidized LDL. Biomacromolecules 2006;7(2):597-603.
19. Chnari E, Nikitczuk J, Wang J, Uhrich K, Moghe P. Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low densitylipoprotein uptake and atherogenesis in macrophages. Biomacromolecules 2006;7(6):1796-805.
20. Wang J, Plourde N, Iverson N, Moghe P, Uhrich K. Nanoscale amphiphilic macromolecules as lipoproteing inhibitors: the role of charge and architecture. Int J Nanomed 2007;2(4):697-705.
21. Plourde N, Kortagere S, Welsh W, Moghe P. Structure-activity relations of nanolipoblockers with the atherogenic domain of human macrophage scavenger receptor A. Biomacromolecules 2009; 10 (6): 1381-91.
22. Chnari E, Lari Hamed B, Tian Lu, Uhrich Kathryn E, Moghe Prabhas V. Nanoscale anionic macromolecules for selective retention of lowdensitylipoproteins. Biomaterials 2005;26:3749-58.
23. Chnari E, Nikitczuck JS, Wang J, Uhrich KE, Moghe PM. Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoproteins uptake and atherogenesis in macrophages. Biomacromolecules 2006;7:1796-805.
24. Chnari E, Nikitczuk J, Uhrich KE, Moghe P. Nanoscale anionic macromolecules can inhibit cellular uptake of differentially oxidized LDL. Biomacromolecules 2006;7(2):597-603.
25. Wang J, Plourde NM, Iverson NM, Moghe PV, Uhrich KE. Nanoscale amphiphilic macromolecules as lipoprotein inhibitors: the role of charge and architecture. Int J Nanomed 2007;2(4):697-705.
26. Harmon A, Uhrich K. In vitro evaluation of amphiphilic macromolecular nanocarriers for systemic drug delivery. J Bioact Compat Polymers 2009; 24 (2): 185-97.
27. Tian L, Yam L, Zhou N, Tat H, Uhrich K. Amphiphilic scorpion-like macromolecules: design, synthesis, and characterization. Macromolecules 2004; 37 (2): 538-43.
28. Tian L, Yam Larry, Zhou Nan, Tat Henry, Uhrich Kathryn E. Amphiphilic scorpion-like macromolecules: design, synthesis, and characterization. Macromolecules 2004;37:538-43.
29. Djordjevic J, del Rosario L, Wang J, Uhrich K. Amphiphilic scorpion-like macromolecules as micellar nanocarriers. J Bioact Compat Polym 2008; 23 (6): 532-51.
30. Wang J, del Rosario L, Demirdirek B, Bai A, Uhrich K. Comparison of PEG chain length and density on amphiphilic macromolecular nanocarriers: selfassembled and unimolecular micelles. Acta Biomater 2009;5(3):883-92.
31. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980;26:171-6.
32. Oorni K, Pentikainen M, Annila A, Kovanen P. Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues. J Biol Chem 1997; 272 (34): 21303-11.
33. Chang M, Potter-Perigo S, Wight T, Chait T. Oxidized LDL bind to nonproteoglycan components of smooth muscle extracellular matrices. J Lipid Res 2001; 42 (5): 824-33.
34. Djordjevic J, Barch M, Uhrich K. Polymeric micelles based on amphiphilic scorpion-like macromolecules: novel carriers for water-insoluble drugs. Pharm Res 2005; 22 (1): 24-32.
35. Steege K, Wang J, Uhrich K, Castner Jr E. Local polarity and microviscosity in the hydrophobic cores of amphiphilic star-like and scorpion-like macromolecules. Macromolecules 2007; 40 (10): 3739-48.
36. Tao L, Uhrich K. Novel amphiphilic macromolecules and their in vitro characterization as stabilized micellar drug delivery systems. J Colloid Interface Sci 2006; 298 (1): 102-10.
37. Fontana G, Licciardi M, Mansueto S, Schillaci D, Giammona G. Amoxicillinloaded polyethyl cyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 2001; 22 (21): 2857-65.
38. Zahr A, Davis C, Pishko M. Macrophage uptake of core-shell nanoparticles surface modified with poly (ethylene glycol). Langmuir 2006; 22 (19): 8178-85.
39. Ogris M, Brunner S, Schuller S, Kircheirs R, Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 1999;6(4):595-605.
40. Yang Z, Sahay G, Sriadibhatla S, Kabanov A. Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA. Bioconj Chem 2008;19:1987-94.
41. Tian Y, Bromberg L, Lin S, Alan Hatton T, Tam K. Complexation and release of doxorubicin from its complexes with pluronic P85-b-poly (acrylic acid) block copolymers. J Control Release 2007; 121 (3): 137-45.
42. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37 (13): 1590-8.
43. Patel S, Datta A. PH effect on the binding of chlorin derivatives with Cremophor EL, a potential drug delivery vehicle. Chem Phys Lett 2005; 413 (1-3): 31-5.
44. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell. 4th ed. Garland Science; 2002.
45. Yoshiizumi K, Nakajima F, Dobashi R, Nishimura N, Ikeda S. Studies on scavenger receptor inhibitors. Part 1: synthesis and structure-activity relationships of novel derivatives of sulfatides. Bioorg Med Chem 2002; 10 (8): 2445-60.
46. Fee C. Size comparison between proteins PEGylated with branched and linear poly (ethylene glycol) molecules. Biotechnol Bioeng 2007; 98 (4): 725-31.
47. DeNoon D. Cholesterol drugs have painful problems. WebMD Health News; 2002.
48. McKenney J. Lipid management: tools for getting to the goal. AmJ Manag Care 2001;7(Suppl. 9):S299-306.